nach oben

Drugs

Erschienen in:

01.09.2010 | Review Article

Opioid Formulations Designed to Resist/Deter Abuse

verfasst von: Professor Robert B. Raffa, Joseph V. Pergolizzi Jr

Erschienen in: Drugs | Ausgabe 13/2010

Einloggen, um Zugang zu erhalten

Abstract

Physicians who prescribe opioid analgesics for patients with moderate to severe chronic pain face a balancing act in the wake of the current publicity regarding abuse (nonmedical use) of prescription pain killers. There is a spectrum of opioid abuse ranging from those who misuse the drug by not following doctor’s orders to those who take the drugs to achieve a high or divert the drugs to the street market for profit. Formulations of opioid analgesics designed to resist or deter abuse have been proposed, and are now either on the market or in the pipeline. These are innovative formulations that make the drug less convenient or less desirable to abusers. This article examines three such new products along with clinical studies that report on their safety and effectiveness. These drugs include extended-release morphine with sequestered naloxone (Embeda®), controlled-release oxycodone in a high-viscosity hard gelatin capsule (Remoxy®) and an immediate-release oxycodone tablet with subtherapeutic niacin as an aversive agent (Acurox® with niacin tablets).

Extended-release morphine with sequestered naltrexone offers a pharmacological barrier in that pellets of morphine surround an internal core of naltrexone (ratio 100: 4 of morphine: naltrexone), which is released if the tablet is compromised by chewing or crushing. The hard gelatin capsule of controlled-release oxycodone was designed to resist tampering and the drug cannot be extracted with a needle. The immediate-release oxycodone formulation with subtherapeutic niacin uses a gel-forming ingredient designed to inhibit inhalation and prevent extraction of the drug for injection. The subtherapeutic niacin is intended to induce flushing and other unpleasant effects if the drug is taken in an excessive quantity. While these drugs hold individual promise, it remains undetermined if they can truly prevent abuse. Drug-seeking individuals are extremely resourceful and show little loyalty to a particular drug when other drugs are available. It is possible that abuse-deterring formulations may divert such individuals to find other drugs that are easier to compromise. Nevertheless, these formulations are important innovations and warrant further study to assess their appropriate role as analgesics.

Abuse is a term that is not universally accepted. For example, some authorities prefer ‘nonmedical use’. We use the term abuse in this article because (i) the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)[1] uses “substance abuse” to describe a “maladaptive pattern of substance use manifested by recurrent and significant consequences related to the repeated use of substances”; and (ii) the US FDA uses the term in relation to the products reviewed.

Diagnostic and statistical manual of mental disorders, DSM-IV. 4th ed. Washington, DC: American Psychiatric Association, 1994

Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999–2006. NCHS data brief, no. 22. Hyattsville (MD): National Center for Health Statistics, 2009 [online]. Available from URL: http://www.cdc.gov/nchs/data/databriefs/db22.htm [Accessed 2010 Jan 12]

Statement by Leonard J. Paulozzi, MD, MPH. Trends in unintentional drug overdose deaths. CDC Congressional testimonial, United States Senate Subcommittee on Crime & Drugs Committee on the Judiciary and the Caucus on International Narcotics Control. March 12, 2008 [online]. Available from URL: http://judiciary.senate.gov/hearings/testimony.cfm?id=3199&wit_id=7036 [Accessed 2010 Jan 14]

Strassels SA. Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm 2009; 15: 556–62PubMed

The National Center on Addiction and Substance Abuse at Columbia University. Under the counter: the diversion and abuse of controlled prescription drugs in the U.S. July 2005 [online]. Available from URL: http://www.casacolumbia.org/absolutenm/articlefiles/380-Under%20the%20Counter%20-%20Diversion.pdf [Accessed 2010 Jan 12]

Gilson AM. The concept of addiction in law and regulatory policy related to pain management: a critical review. Clin J Pain 2010; 26: 70–7PubMedCrossRef

Gilson AM, Maurer MA, Joranson DE. State medical board members’ belief about pain, addiction, and diversion and abuse: a changing regulatory environment. J Pain 2007; 8: 682–91PubMedCrossRef

Buppert C. The legal pitfalls in prescribing opioids. Medscape 2009 Nov 18 [online]. Available from URL: http://www.medscape.com/viewarticle/712414_print [Accessed 2010 Jan 14]

Walker EP. Docs urge FDA to go easy on opioid risk reduction strategies. Medpage Today 2009 May 27 [online]. Available from URL: http://www.medpagetoday.com/PainManagement/PainManagement/14403 [Accessed 2010 Jan 14]

10.

Wright IV C, Schnoll S, Bernstein D. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective. Ann N Y Acad Sci 2008; 1141: 284–303PubMedCrossRef

11.

Controlled substances act. Wikipedia [online]. Available from URL: http://en.wikipedia.org/wiki/Controlled_Substances_Act [Accessed 2010 Jan 14]

12.

Trescott AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006; 91: 1–40

13.

Zacny JP, Lichtor SA. Nonmedical use of prescription opioids: motive and ubiquity issues. J Pain 2008; 9: 473–86PubMed

14.

Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtain abuse: who is the target? Expert Opin Investig Drugs 2009; 18: 255–63PubMedCrossRef

15.

Butler SF, Fernandez KC, Chang A, et al. Measuring attractiveness for abuse of prescription opioids. Pain Med 2010; 11:67–80PubMedCrossRef

16.

Butler SF, Benoit C, Budman SH, et al. Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J 2006; 3: 5–16PubMedCrossRef

17.

NDA 22-324 Remoxy XRT™ (oxycodone controlled-release) capsules CII. Advisory committee briefing materials for the Anesthetic Life Support Drugs Advisory Committee meeting of November 13, 2008. San Mateo (CA): Pain Therapeutics, Inc., 2008 Oct 12 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4395b1-02-PAIN.pdf [Accessed 2010 Jan 18]

18.

Comptom WM, Volkow MD. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006; 83 Suppl. 1: S4–7CrossRef

19.

Katz NP, Buse DC, Budman SH, et al. Development and preliminary experience with an ease of extractability rating system for prescription opioids. Drug Dev Ind Pharm 2006; 32: 722–46CrossRef

20.

Karteem SS. Abuse deterrent formulations [online]. Available from URL: http://www.ashp.org/DocLibrary/MemberCenter/SHACCP/Abuse.aspx [Accessed 2010 Jan 14]

21.

Rappaport BA. Regulatory issues in reviewing and approving opioid analgesics. FDA: Silver Spring (MD), 2009 Feb 10 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM163692.pdf [Accessed 2010 Jan 27]

22.

Talwin® Nx C_IV prescribing information 2008 [online]. Available from URL: http://products.sanofi-aventis.us/talwin_nx/talwin_nx.pdf [Accessed 2010 Jan 16]

23.

Suboxone. Important information for physicians. 2007 [online]. Available from URL: http://www.suboxone.com/pdfs/Physician_Labeling_Brochure.pdf [Accessed 2010 Jan 16]

24.

US FDA. Warning letter dated October 8, 2009 to King Pharmaceuticals Inc. [online]. Available from URL: http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm186771.htm [Accessed 2010 May 5]

25.

Pain Therapeutics at Cowen and Company Healthcare Conference, March 9, 2010 [online]. Available from URL: „http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=PTU&item_id=2782437 [Accessed 2010 Mar 28]

26.

Acurox. April 22, 2010, Advisory Committee meeting background package [online]. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM209141.pdf [Accessed 2010 May 5]

27.

FDA Panel vote against Acurox [online]. Available from URL: http://www.dailymarkets.com/stocks/2010/04/26/fdapanel-vote-against-acurox/ [Accessed 2010 May 5]

28.

Acurox® with niacin tablets [online]. Available from URL: http://acurapharm.com/products/acurox-tablets/ [Accessed 2010 Mar 28]

29.

Statement of Purdue Pharma LP regarding FDA’s approval of reformulated OxyContin® (oxycodone HCl controlled-release) tablets [press release]. Purdue Pharma, 2010 Apr 5 [online]. Available from URL: http://www.purduepharma.com/pressroom/news/20100405.htm [Accessed 2010 May 5]

30.

OxyContin: questions and answers. US FDA, 2010 Apr 5 [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm207196.htm [Accessed 2010 May 5]

31.

Butler SF, Budman SH, Licari A, et al. National addiction vigilance intervention and prevention program (NAVIPPRO™): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf 2008; 17: 1142–54PubMedCrossRef

32.

Embeda® prescribing information. King Pharmaceuticals, Inc., 2009 Jun [online]. Available from URL: http://www.kingpharm.com/products/product_document.cfm?brand_name=Embeda&product_specific_name=CII&document_type_code=PI [Accessed 2010 Jan 17]

33.

Stauffer J, Setnik B, Sokolowska M, et al. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled study. Clin Drug Investig 2009; 29: 777–90PubMedCrossRef

34.

A morphine/naltrexone combination (Embeda) for pain. Med Lett Drugs Ther 2010; 52: 22–3

35.

Katz N, Sun S, Johnson F, et al. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain 2010 Apr; 11(4): 303–11PubMedCrossRef

36.

Raehal KM, Lowery JJ, Bharmidipati M, et al. In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. J Pharmacol Exp Ther 2005; 313: 1150–62PubMedCrossRef

37.

Lipman AG. What have we learned from OxyContin? J Pain Palliat Care Pharmacother 2003; 17: 1–4

38.

Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010; 152: 85–92PubMed

39.

Dhalla IA, Mamdani MM, Sivilotti MLA, et al. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009 Dec 8; 181(12): 891–6PubMedCrossRef

40.

Rauck RL. What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review. Pain Pract 2009; 9: 468–79PubMedCrossRef

41.

Pain-Topics.org news. Canadian study distorts Rx-opioid-related deaths. December 10, 2009 [online]. Available from URL: http://updates.pain-topics.org/2009/12/canadian-study-distorts-rx-opioid.html [Accessed 2010 Apr 20]

42.

Webster LR. PTI-821: sustained-release oxycodone using gel-cap technology. Expert Opin Invest Drugs 2007; 16: 359–66CrossRef

43.

Gilderman L, Butera P, Gilmore D, et al. Remoxy: a new opioid drug with effective analgesia and abuse-resistance [abstract]. J Pain 2006; 4 Suppl. 1: S41

44.

Ji P. Remoxy in vivo abuse resistance studies [PowerPoint slides]. 2008 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4395s1-03-FDA-Ji.ppt [Accessed 2010 Jan 19]

45.

Sathyan G, Sivakumar K, Thipphawong J. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin 2008; 24: 297–305PubMedCrossRef

46.

Friedmann N, de Kater AW, Butera PG, et al. Remoxy™, a novel drug candidate, deters oxycodone abuse in humans [poster]. 3rd International Congress, World Institute of Pain; 2004 Sep 21–25; Barcelona [online]. Available from URL: http://www.lifetreeresearch.com/media/abstracts/WorldPainCongressRemoxy_Sept04.pdf [Accessed 2010 Jun 10]

47.

Study AP-ADF-101. Acura Pharmaceuticals website [online]. Available from URL: http://acurapharm.com/products/acurox-tablets/study-ap-adf-101 [Accessed 2010 Jan 19]

48.

Acurox tablets. Study AP-ADF-106 [online]. Available from URL: http://acurapharm.com/products/acurox-tablets/study-ap-adf-106 [Accessed 2010 Jul 20]

49.

Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of OxyContin® and other opioid analgesics in the United States: 2002–2004. J Pain 2005; 6: 662–72PubMedCrossRef

50.

Sung HE, Richter L, Vaughan R, et al. Nonmedical use of prescription opioids among teenagers in the United States: trends and correlates. J Adolescent Health 2005; 37: 44–51CrossRef

51.

Let’s talk … ways to take oxycontin. Drugs Forum [online]. Available from URL: http://www.drugs-forum.com/forum/showthread.php?t=28258 [Accessed 2010 Jan 18]

52.

How do I take oxycodone/APAP? Topix.com [online]. Available from URL: http://www.topix.com/forum/drug/oxycontin/TAQ163V7ME8KM4IS2 [Accessed 2010 Jan 18]

53.

Oxycontin. UrbanDictionary.com. Oxycontin [online]. Available from URL: http://www.urbandictionary.com/define.php?term=oxycontin [Accessed 2010 Jan 18]

Titel: Opioid Formulations Designed to Resist/Deter Abuse
verfasst von: Professor Robert B. Raffa
Joseph V. Pergolizzi Jr
Publikationsdatum: 01.09.2010
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 13/2010
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/11537940-000000000-00000

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Opioid Formulations Designed to Resist/Deter Abuse

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13/2010

Tapentadol Immediate Release

Guanfacine Extended-Release

Pyelonephritis in Pregnancy

Octreotide Long-Acting Release (LAR)

Pharmacoeconomic Considerations in the Treatment of Multiple Sclerosis

Bendamustine